ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
5.46
-0.12
( -2.15% )
Updated: 00:19:11

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
5.46
Bid
5.25
Offer
5.50
Volume
2,979
5.2501 Day's Range 5.50
4.76 52 Week Range 20.72
Market Cap
Previous Close
5.58
Open
5.43
Last Trade
50
@
5.25
Last Trade Time
00:24:38
Financial Volume
US$ 15,998
VWAP
5.3702
Average Volume (3m)
40,100
Shares Outstanding
29,609,814
Dividend Yield
-
PE Ratio
-12.23
Earnings Per Share (EPS)
-0.44
Revenue
-
Net Profit
-13.07M

About Telomir Pharmaceuticals Inc

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oralin situtherapeutic treatment for human stem cells. Its goal is to develop and commercialize new tre... Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oralin situtherapeutic treatment for human stem cells. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Tampa, Florida, USA
Founded
1970
Telomir Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TELO. The last closing price for Telomir Pharmaceuticals was US$5.58. Over the last year, Telomir Pharmaceuticals shares have traded in a share price range of US$ 4.76 to US$ 20.72.

Telomir Pharmaceuticals currently has 29,609,814 shares in issue. The market capitalisation of Telomir Pharmaceuticals is US$159.89 million. Telomir Pharmaceuticals has a price to earnings ratio (PE ratio) of -12.23.

TELO Latest News

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

TAMPA, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development...

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines...

New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces broadcasting of its national business show that will air as a sponsored program on Bloomberg TV on Saturday...

Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- FMW Media Works' New to The Street televised business show will feature Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ($TELO) ("Company"), a...

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging...

Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Telomir’s pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase New York...

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused...

Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
10.11.865671641795.366.285.131284055.53183527CS
4-0.49-8.235294117655.957.195.05382905.86554269CS
120.469.259.395401006.88945666CS
26-1.54-22720.724.76539437.77507693CS
52-1.54-22720.724.76539437.77507693CS
156-1.54-22720.724.76539437.77507693CS
260-1.54-22720.724.76539437.77507693CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TM1OTerra Metals Ltd
AUD 0.038
(245.45%)
2.9M
ME1OEMelodiol Global Health Ltd
AUD 0.003
(200.00%)
10.2k
TM1Terra Metals Ltd
AUD 0.073
(135.48%)
88.27M
JAVJavelin Minerals Ltd
AUD 0.002
(100.00%)
3.8M
D2OOADuxton Water Limited
AUD 0.04
(90.48%)
341
PR1OAPure Resources Ltd
AUD 0.004
(-50.00%)
50k
1CGOOne Click Group Ltd
AUD 0.002
(-50.00%)
490.53k
SGAOSarytogan Graphite Ltd
AUD 0.013
(-45.83%)
238.22k
BRXOABelararox Ltd
AUD 0.013
(-40.91%)
264.14k
CYPOACynata Therapeutics Ltd
AUD 0.055
(-38.89%)
62.4k
TM1Terra Metals Ltd
AUD 0.073
(135.48%)
88.27M
REDRed 5 Limited
AUD 0.405
(-9.50%)
82.44M
BTRBrightstar Resources Limited
AUD 0.018
(24.14%)
67.68M
TLSTelstra Corporation Limited
AUD 3.61
(0.84%)
36.03M
BFCBeston Global Food Company Limited
AUD 0.003
(0.00%)
31.73M

Your Recent History

Delayed Upgrade Clock